COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804


Print ISSN:-2581-5024

Online ISSN:-2581-5016

CODEN : IIJOBU

Current Issue

Year 2020

Volume: 6 , Issue: 1

Article Access statistics

Viewed: 711

Emailed: 0

PDF Downloaded: 272

IP International Journal of Ocular Oncology and Oculoplasty


Ocular surface squamous neoplasia (OSSN)


Full Text PDF Share on Facebook Share on Twitter


Author Details : Jayasri Krishnaraj, Sagnik Surya Das, Kalaimamani Ezhil Vendhan

Volume : 2, Issue : 1, Year : 2016

Article Page : 19-30


Suggest article by email

Abstract

OSSN is the third most common conjunctival malignancy worldwide and is commonest in the tropics. It is a tumor of the elderly and is usually misdiagnosed, as it resembles benign conditions like pinguecula and pterygium. We are now equipped with a wide array of investigative modalities ranging from Impression cytology to confocal microscopy. Treatment of choice for OSSN is surgical excision with cryotherapy and may be combined with other modalities like immunotherapy, topical chemotherapeutic agents and radiotherapy. Recently pegylated interferon has shown promising results in management of recurrent OSSN.

Key Words:
Cryotherapy, Human Papilloma Virus, Impression cytology, Interferon, Squamous neoplasia

How to cite : Krishnaraj J, Das S S, Vendhan K E, Ocular surface squamous neoplasia (OSSN). IP Int J Ocul Oncol Oculoplasty 2016;2(1):19-30

Copyright © 2016 by author(s) and IP Int J Ocul Oncol Oculoplasty. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)